Dr. Greg Hiemenz, President and CEO
Dr. Hiemenz is a dynamic, versatile business leader with over a decade of experience in leading the development of new products and growing business. He is skilled in creating winning market-based strategies and executing them through cross-functional teams and is able to quickly grasp new technologies and translate them into strategy and value propositions. Prior to InnoVital Systems, Dr. Hiemenz served as Vice President of the Advanced Technologies Division at Techno-Sciences Inc. (TSI). During his tenure at TSI, Dr. Hiemenz spearheaded research and development of advanced technologies into military and commercial markets and was responsible for creating a new product line for protecting soldier’s spines during IED blasts and helicopter crashes. He has worked closely with academia to evaluate and transition cutting-edge technologies into marketable products. He currently leads a highly skilled, multi-disciplinary team engineers while directing business development and proposal efforts, supervising personnel and staffing needs, managing intellectual property and business agreements, and performing market analyses for emerging technologies. Prior to joining TSI, Dr. Hiemenz spent several years at a major defense contractor serving as a technical specialist and integrated product team leader. Dr. Hiemenz graduated Summa Cum Laude with a B.M.E. in Mechanical Engineering at Catholic University of America where he earned several awards for being the top ranked student in the School of Engineering. He subsequently earned his M.S. and Ph.D. in Aerospace Engineering at UMD under a Graduate School Fellowship. Because of his research successes, he was awarded a Vertical Flight Foundation fellowship from the American Helicopter Society and the AIAA Hal Andrews Young Engineer of the Year Award in 2008. He has published over 20 conference and journal papers and has 7 patents issued and another 6 patents pending.
Dr. William Krimsky, Chief Science Officer
Dr. Krimsky is Director and Chief of Interventional Pulmonary Medicine at MedStar Franklin Square Medical Center. He has made a significant commitment to the invention, development and design of supportive devices for pulmonary and critical care patients who are often without viable treatment options. Dr. Krimsky is an inventor on 16 published patents, 14 of which have been licensed or purchased by industry, and another 12 patents that are as yet unpublished. Dr. Krimsky was involved in each step, from concept to market, in the development of CSA Medical’s spray cryotherapy truFreeze® system. Dr. Krimsky has served as a site PI, along with other national thought leaders, on several seminal pulmonary technology trials including the Rox Medical WALK trial, the PneumRx RENEW trial and the Broncus Technologies EASE trial. As a member of the American College of Chest Physicians, Dr. Krimsky has participated in lobbying the AMA/Specialty Society Relative Value Scale Update Committee (RUC) for CPT codes for procedures ranging from endobronchial ultrasound, navigational bronchoscopy and endobronchial valves. Dr. Krimsky and his team have worked to incorporate a variety of different medical and surgical specialties in the care of patients with advanced lung disease in an effort to provide integrated, cost-effective care. Dr. Krimsky is a graduate of Middlebury College, University of Pittsburgh School of Medicine, Johns Hopkins University/Sinai Hospital Program in Internal Medicine (where he served as Chief Resident), and the Dartmouth-Hitchcock Medical Center pulmonary medicine and critical care medicine fellowship training program.
Dr. Amit Shah, Chief Medical Officer
Dr. Shah’s experience with medical technology spans R&D, clinical testing, regulation, standards-setting, investment, commercialization, and facility / end-user adoption. As the Founding Director of the office for technology commercialization for a $4 billion regional healthcare system in the Maryland and Washington, D.C. region, Dr. Shah vetted nearly 200 medical device and software inventions, ultimately fostering multiple academic-industry co-development initiatives and technology out-licenses. Serving as a Medical Officer at the Food and Drug Administration’s (FDA) Office of Device Evaluation, Dr. Shah led the FDA’s clinical review of multiple medical device applications including PMA, 510(k) and pre-IDE submissions. Dr. Shah’s formal training in and experience with clinical research (from trial design to execution to data analysis and presentation) added a unique depth to his reviews. Dr. Shah has also engaged with the Association for the Advancement of Medical Instrumentation to help safeguard patients through standards-setting in patient monitoring. Dr. Shah has served as a Clinical Partner at a leading healthcare venture capital investment firm and continues to advise angel investment groups. He is the Physician Representative to the Value Analysis / Technology Adoption Committee at one of the largest hospitals in the country, where he still practices emergency medicine and enjoys teaching resident physicians and medical students at the bedside.